1. Home
  2. BOLD vs LGCL Comparison

BOLD vs LGCL Comparison

Compare BOLD & LGCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • LGCL
  • Stock Information
  • Founded
  • BOLD 2018
  • LGCL 2009
  • Country
  • BOLD United States
  • LGCL China
  • Employees
  • BOLD N/A
  • LGCL N/A
  • Industry
  • BOLD
  • LGCL
  • Sector
  • BOLD
  • LGCL
  • Exchange
  • BOLD Nasdaq
  • LGCL NYSE
  • Market Cap
  • BOLD 49.5M
  • LGCL 43.2M
  • IPO Year
  • BOLD 2024
  • LGCL 2024
  • Fundamental
  • Price
  • BOLD $1.51
  • LGCL $0.49
  • Analyst Decision
  • BOLD Buy
  • LGCL
  • Analyst Count
  • BOLD 3
  • LGCL 0
  • Target Price
  • BOLD $22.50
  • LGCL N/A
  • AVG Volume (30 Days)
  • BOLD 82.4K
  • LGCL 187.0K
  • Earning Date
  • BOLD 03-27-2025
  • LGCL 11-22-2024
  • Dividend Yield
  • BOLD N/A
  • LGCL N/A
  • EPS Growth
  • BOLD N/A
  • LGCL 11.49
  • EPS
  • BOLD N/A
  • LGCL 0.14
  • Revenue
  • BOLD N/A
  • LGCL $173,306,912.00
  • Revenue This Year
  • BOLD N/A
  • LGCL N/A
  • Revenue Next Year
  • BOLD N/A
  • LGCL N/A
  • P/E Ratio
  • BOLD N/A
  • LGCL $3.42
  • Revenue Growth
  • BOLD N/A
  • LGCL N/A
  • 52 Week Low
  • BOLD $1.42
  • LGCL $0.43
  • 52 Week High
  • BOLD $14.72
  • LGCL $3.76
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • LGCL N/A
  • Support Level
  • BOLD N/A
  • LGCL N/A
  • Resistance Level
  • BOLD N/A
  • LGCL N/A
  • Average True Range (ATR)
  • BOLD 0.00
  • LGCL 0.00
  • MACD
  • BOLD 0.00
  • LGCL 0.00
  • Stochastic Oscillator
  • BOLD 0.00
  • LGCL 0.00

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.

Share on Social Networks: